The primary aim of this study was evaluation of the effi cacy of telmisartan (angiotensin II receptor blocker-AT 1 blocker) on blood pressure in 10 patients with renal impairment in moderate or advanced stages of renal insuffi ciency and not dependent on haemodialysis. Its eff ect on proteinuria, renal function (represented by serum urea, creatinine, glomerular fi ltration), evaluation of overall therapy compliance in comparison with a previously prescribed angiotensin converting enzyme inhibitors (ACEI) were secondary aims. Considering the presence of left ventricle hypertrophy in all patients as a marker of hypertensive cardiopathy, the eff ect of telmisartan therapy on non-invasive cardiovascular parameters (ECG, echocardiography, and assessment of heart rate variability-HRV) was also evaluated.
INTRODUCTION
Inhibition of renin-angiotensin-aldosterone system (RAA) results in reduced progression and diminished clinical symptoms in many cardiovascular diseases. The treatment of these drugs has been proven multicentric trials, the results of which have been published over the past fi ve years [1] [2] [3] . Experimental and clinical trials focused at renal parameters have also been performed [4] [5] [6] [7] . The evidence for the positive eff ects of angiotensin converting enzyme (ACEI) and angiotensin II receptor blockers (ARBs) exceed their eff ect on the blood pressure resulted in the opinion that the RAA system plays an important role in the pathophysiology and progression of renal diseases. The octapeptide angiotensin II (Ang-II) is the main effector of RAA system with a lot of renal consequences ranging from the haemodynamic control to the infl uence on the morphology of renal cells, tubular functions, immunomodulative and anti-infl ammatory eff ects, as far as the interactions with other humoral or endocrine systems. The majority of known Ang-II eff ects are mediated by angiotensin receptors-type 1 (AT1). It was found that local renal Ang-II enhances the glomerular eff erent arteriolar tension and thus the intraglomerular pressure, glomerular permeability and proteinuria. ACEI are potent blockers of Ang-II production. A positive infl uence of ACEI on the further progression of glomerulopathy and renal insuffi ciency has been demonstrated in a number of experimental and clinic trials, particularly in patients with diabetic nephropathy 9, 10 . ACEI slowed the rate of progression of renal insuffi ciency in these patients and reduced albuminuria. Two studies (AIPRI, REIN) also showed marked reduction in the progression of renal insuffi ciency in non-diabetic nephropathy 8, 11 . As in cardiBiomed. Papers 148 (1) , 69-73 (2004) ology, the more marked nephroprotective eff ect of ARBs therapy was expected in nephrology as well, especially for more complex Ang-II blockade. Trials with losartan, valsartan and candesartan showed antihypertensive eff ects comparable to other trials with ACEI and practically the same nephroprotective eff ect [12] [13] [14] . Thus the contemporary experience with the renal eff ects of ARBs in chronic nephropathy patients is much lower than that with ACEI.
In connection with these well-known facts we were interested in the eff ect of Ang-II receptor blocker telmisartan (Micardis) in patients with renal insuffi ciency without dialysis treatment, with moderate proteinuria, hypertension and hypertensive cardiopathy. We selected the patient group with ACEI intolerance, mostly manifest as irritable cough. The primary aim of our study was evaluation of the effi cacy of telmisartan antihypertensive treatment of patients with renal disease in moderate or advanced stages of renal insuffi ciency. The secondary aims were the eff ects on proteinuria, serum creatinine and potassium as well as the evaluation of the infl uence on cardiovascular system, assessment of patient compliance of telmisartan compared to previously prescribed ACEI.
MATERIALS AND METHODS
The study included 10 patients with diabetic and non-diabetic renal impairment, followed long-term in our specialised facility. Four had diabetic nephropathy, fi ve had chronic glomerulonephritis and one had vascular nephrosclerosis and interstitial nephritis. Their diagnosis was based on clinical and laboratory fi ndings and in 50 % on renal biopsy. Proteinuria above 1 g/24h, hypertension and the intolerance of ACEI were common denominators in all patients. Exclusion criteria were: renovascular or malignant hypertension, history of myocardial infarction or cerebral events, claudications, chronic heart failure, chronic liver or lung diseases, systemic diseases, steroid or immunosuppressive treatment, alcohol abuse.
At the beginning of the study, each patient underwent physical examination, blood pressure (BP) and heart rate (HR) measurement, laboratory testing (serum Na, K, Ca, P, urea, creatinine, uric acid, ALT, AST, ALP, GMT, total cholesterol, triglycerides, glucose, total proteins, albumin), total blood count. Glomerular fi ltration was assessed by creatinine clearance (CLR = urine creatinine x 24 hour diuresis / serum creatinine and result was converted to patient's body surface, ml/s/m 2 ); proteinuria was calculated as urine protein concentration after the 24-hour samples (g/day). All patients underwent non-invasive ambulatory 24-hour BP monitoring (ABPM) by arm-cuff method with pressure monitor Cardiette BP One (Elletronica Trentina S.p.A, Italy), ECG, maximum or symptom-limited bicycle ergometry. A transthoracic echocardiography (Hewlett Packard ImagePoint) was performed by the same physician to assess the global systolic function (left ventricle ejection fraction, LVEF), LV enddiastolic diameter, semiquantitative LV diastolic function (E, A wave, type of dysfunction) and valve function.
Heart rate variability (HRV) was used for assessment of the sympathovagal balance and neuroendocrine activation, which are infl uenced both by impaired metabolic parameters of renal insuffi ciency and by RAA system (Fig. 1) . The measurement was performed under standardised conditions with telemetric computer-aided system VariaPulse TF4 before and after 1-year telmisartan therapy. The used method of HRV measurement is based on short-term spectral analysis of HRV during modifi ed orthoclinostatic test (supine-standing-supine), which is a functional test with vagal load 16 ( Fig. 1) . The results were processed by the software program VariaCa 2.0 enabling to assess so-called the "functional age of the autonomic nervous system" (ANS) in comparison with an age-matched healthy control population. Using a scale from -5 to +5, the complex parameters of ANS were evaluated, i.e. parameter "vagal activity", parameter "sympathovagal balance" and parameter "total score" 17 . Depression of total score means a sympathetic, i.e. neuroendocrine activation.
Laboratory testing was performed monthly over 6 months to observe any adverse eff ects of the treatment, the functional renal testing, ABPM, echocardiography and HRV measurement after 3, 6 and 12 months. Ergometry was repeated after 6 months.
The pharmacotherapy was not changed during the study. Telmisartan was added in the dose of 40 mg/day at the beginning of the study. After 14 days the dose was increased to 80 mg/day. Statistical analyses using ANOVA compared the results before and after 12 months of therapy with telmisartan.
RESULTS AND DISCUSSION
The average initial daytime systolic blood pressure (s-BPd, from 6 AM to 10PM) was 149.6 ± 19.7 mm Hg, average night-time s-BP (s-BPn, from 10PM to 6AM) was 145.8 ± 23 mm Hg, average diastolic daytime BP (d-BPd) was 90.6 ± 2.6 mm Hg, night-time d-BP (d-BPn) was 88.9 ± 13.6 mm Hg. After 1 year of treatment with telmisartan, average s-BPd was 116.6 ± 37.7 mm Hg, s-BPn was 129.5 ± 8.8 mm Hg, d-BPd 83.5 ± 7,3 mm Hg, d-BPn was 79.3 ± 5.7 mm Hg (Fig. 2) . A signifi cant reduction (p < 0.05) of BP was reached, meeting guideline values for treatment of hypertension with proteinuria and renal impairment. During 1-year laboratory testing no signifi cant shift in results of serum potassium was registered. 24 hour diuresis and creatinine clearance (from 0.55 ml/sec before to 0.68 ml/ sec after treatment) increased slightly together with increased serum creatinine (from 207.2 to 224 µmol/l), urea (from15.1 to 17.6 mmol/l) and uric acid (from 354 to 403 µmol/l). The diff erences were not signifi cant. There was a signifi cant reduction of proteinuria (from 2.37 to 1.27 g/24hour, p < 0 .05) (Fig. 3) (average LV EF = 50.4 ± 2.9 %), after treatment 40-55 % (average LVEF = 48.6 ± 4.5 %, p < 0.05). All patients had diastolic dysfunction, mostly moderate impairment of LV relaxation continuing throughout the study. There was no serious valve dysfunction. The LV cavity diameter did not change. After 6 months, the ergometric testing revealed a moderate worsening of workload capacity.
In contrast with the optimisation of BP the assessment of HRV revealed neither improvement, nor further progression of the impaired sympathovagal balance, particularly as measured by absolute depression of vagal activity. Only one patient with interstitial nephritis and nephrosclerosis revealed a marked improvement of HRV parameters (Fig. 4) .
Telmisartan was tested for treatment in patients with hypertension, proteinuria and moderate or advanced renal insuffi ciency. Among the sartans, it has the longest biological half-time (over 24 hours). This enables to prescribe it in a single daily dose with well-controlled BP over 24 hours. Its gastrointestinal absorption is rapid, biotransformation occurs in liver and small intestine. It is then eliminated by faeces in 98 %. There is only 2 % renal elimination. Therefore the telmisartan dosage does not have to be adjusted to the degree of renal insuffi ciency. The liver metabolism is not mediated by cytochrome P-450, so the risk of drug interaction is minimised, a factor highly desirable in patients with renal insuffi ciency and necessary polypragmasia.
In harmony with the literature data 19 , a signifi cant hypotensive (antihypertensive) eff ect of telmisartan was found. Practically all patients reached the optimal BP, in addition with very good patient compliance. There were no adverse eff ects in any patient, causing therapy withdrawal. Over 1 year of therapy, proteinuria significantly decreased (p < 0.05) independent of the aetiology of the nephropathy. There was no registered signifi cant elevation of serum potassium, causing the interruption of the treatment, changes in liver markers, concentration of other minerals (Na, Ca, P, Cl), total proteins or albumin. The concentration of urea, creatinine and uric acid increased non-signifi cantly, together with a non-signifi cant elevation of glomerular fi ltration measured by creatinine clearance. The explanation of this tendency was based on the fact that primary and secondary renal diseases are usually of a progressive character. It is evident particularly both in chronic non-infl ammatory and infl ammatory nephropathies with proteinuria over 1 g/24 hour. With slow glomerular fi ltration a decrease 5-10 ml/min/year (0.08-0.16ml/sec/year), patients with initially normal glomerular fi ltration reach the end stage of renal disease requiring dialysis in 10-20 years 19 . The rate of progression of renal disease is individual with various infl ammatory factors involvement, insuffi cient compensation of metabolic parameters related to patient compliance, motivation and self-discipline. There are also secondary factors, common for all nephropathies, particularly elevation of systemic BP and intraglomerular pressure. In contrast to the simplicity of measuring systemic BP, the assessment of intraglomerular pressure is clinically diffi cult and it is an indirect estimate only. It is based on measurement of renal blood fl ow and glomerular fi ltration. The nephroprotective eff ects of ACEi and ABRs consist in positive infl uence on these hemodynamic parameters -they reduce systemic BP, cause selective glomerular eff erent arteriolar dilation and thus they decrease the intraglomerular pressure more than other antihypertensive agents. The mechanism of nephroprotective eff ects of ACEI and ABRs is obviously complex, including also non-hemodynamic factors as restriction of glomerular hypertrophy, positive infl uences on glomerular permeability to proteins, reduced renal interstitial infi ltration macrophages and formation of the growth factors. Due to ACEI or ABRs activity there is diminished progression of interstitial fi brosis. If we consider the result of our work in this context, it can be assumed that the described positive eff ects of telmisartan are exerted in preserved and reactivity capable glomerules, while it could not be in the non-functional ones. So there occurred an inter-year elevation of serum creatinine and urea, even though only a moderate and non-signifi cant one. This is in agreement with large randomised trials (Collaborative Study Group, RENAAL, IDNT), that found a marked reduction of the progression of renal insuffi ciency in a defi ned part of patients with initial creatinine between 120 and 265 µmol/l, while in others this parameter was impaired [12] [13] [14] . During a year treatment, none of 10 patients manifested cardiac deterioration nor required hospitalisation for acceleration of angina pectoris or heart failure. The subjectively evaluated quality of life was also much improved. There were no objective tools to assess the quality of life parameters. However, it can be derived from the fact that patients keep asking telmisartan to be prescribed in spite of their obligation to partially cover its costs themselves. After 1-year treatment, the parameters of ANS revealed further worsening of the impaired sympathovagal balance. A metabolic explanation was improbable. Nevertheless research evidence in this topic is very scarce. In addition, the published studies evaluate ANS only in dialysed patients. Akselrod 20 , Bonaduce 21 , Taylor 22 found positive eff ects of ACEi on ANS, i.e. on HRV parameters. So far, a similar eff ect has not been proved in sartans (ABRs). Heusser 21 described further HRV reduction analogous to that registered in the present study. In agreement with this author, the explanation may be found in central effect of accumulated Ang-II, as a common side eff ect of ABRs therapy in contrary to ACEI one. From the point of ANS the potential positive eff ect can be expected from the combination therapy with ABRs and ACEI.
CONCLUSION
Telmisartan, like other previously reported sartans, eff ec tively decreases the blood pressure and proteinuria in patients with moderate and advanced renal insufficiency regardless to its cause. It is well tolerated, it does nor aff ect other biochemical parameters. During a one-year study, no impairment of left ventricle functions was observed. However, a year follow-up is too short to assess an eventual improvement. On the other hand a further worsening of sympathovagal balance was registered, so far without clinical consequences. Further studies should deal with this topic for its more detailed elucidation.
